Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Broad-spectrum aerosol add-on therapy for depression with chest tightness symptoms
ChiCTR2600135554Phase 4Completed
- Sponsor
- Hangzhou Seventh People's Hospital
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of escitalopram in major depressive disorder (MDD) (2 arms), sponsored by Hangzhou Seventh People's Hospital. Primary endpoint: Reduction score for chest tightness-related symptoms. Started Jul 2023; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2600135554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135554.